` OBSN (Obseva SA) vs Swiss Market Index Comparison - Alpha Spread

O
OBSN
vs
S
Swiss Market Index

Over the past 12 months, OBSN has underperformed Swiss Market Index, delivering a return of 0% compared to the Swiss Market Index's 1% drop.

Stocks Performance
OBSN vs Swiss Market Index

Loading
OBSN
Swiss Market Index
Add Stock
www.alphaspread.com

Performance Gap
OBSN vs Swiss Market Index

Loading
OBSN
Swiss Market Index
Difference
www.alphaspread.com

Performance By Year
OBSN vs Swiss Market Index

Loading
OBSN
Swiss Market Index
Add Stock

Competitors Performance
Obseva SA vs Peers

Swiss Market Index
OBSN
ABBV
AMGN
GILD
VRTX
Add Stock

Obseva SA
Glance View

Market Cap
140.6k CHF
Industry
Biotechnology

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

OBSN Intrinsic Value
Not Available
O
Back to Top